The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Eisai
Phase 1 study of E7046, an inhibitor of the PGE2 receptor EP-4, that targets immunosuppressive myeloid cells in the tumor microenvironment (NCT02540291).
 
David S. Hong
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Lilly; Merck; Mirati Therapeutics; miRNA Therapeutics; Novartis; Pfizer
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
 
Eunice Lee Kwak
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen
 
Matthew Guo
Employment - Eisai
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Eisai
 
Chean Eng Ooi
Employment - Eisai
 
Ozlem Ataman
No Relationships to Disclose
 
Aurelien Marabelle
Honoraria - Amgen; Bristol-Myers Squibb; Merck; Pfizer; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Pfizer; Roche
Speakers' Bureau - Gerson Lehrman Group; Guidepoint Global